These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36527880)

  • 21. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
    Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
    World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.
    Horiguchi H; Hatakeyama S; Yoneyama T; Yoneyama MS; Tanaka T; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Yoshizawa T; Hashimoto Y; Kawaguchi T; Ohyama C
    Urol Oncol; 2021 Apr; 39(4):238.e9-238.e17. PubMed ID: 33308976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New drug approval: Nivolumab for adjuvant treatment of patients with PD-L1-positive (≥1%), muscle invasive urothelial carcinoma who are at high risk of recurrence after radical resection].
    Bellio H; Benderra MA
    Bull Cancer; 2022 Oct; 109(10):992-993. PubMed ID: 35995615
    [No Abstract]   [Full Text] [Related]  

  • 24. Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder.
    Tosev G; Wahafu W; Reimold P; Damgov I; Schwab C; Aksoy C; Kaczorowski A; Stenzinger A; Nyarangi-Dix J; Hohenfellner M; Duensing S
    Sci Rep; 2021 Jul; 11(1):14244. PubMed ID: 34244564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
    Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
    Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J
    Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.
    Mahmoud AM; Frank I; Orme JJ; Lavoie RR; Thapa P; Costello BA; Cheville JC; Gupta S; Dong H; Lucien F
    BMC Urol; 2022 Jun; 22(1):90. PubMed ID: 35751046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
    Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
    Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
    Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
    Mao S; Zhang J; Guo Y; Zhang Z; Wu Y; Zhang W; Wang L; Geng J; Yan Y; Yao X
    Drug Des Devel Ther; 2019; 13():291-300. PubMed ID: 30666091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
    Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Perrone F; Nicolai N; Catanzaro M; Biasoni D; Torelli T; Piva L; Stagni S; Salvioni R; Mariani L; Colecchia M
    Clin Genitourin Cancer; 2018 Apr; 16(2):e403-e410. PubMed ID: 29111177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
    Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
    J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
    Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
    Rouanne M; Radulescu C; Adam J; Allory Y
    World J Urol; 2021 May; 39(5):1345-1355. PubMed ID: 33141317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
    Bajorin DF; Witjes JA; Gschwend JE; Schenker M; Valderrama BP; Tomita Y; Bamias A; Lebret T; Shariat SF; Park SH; Ye D; Agerbaek M; Enting D; McDermott R; Gajate P; Peer A; Milowsky MI; Nosov A; Neif Antonio J; Tupikowski K; Toms L; Fischer BS; Qureshi A; Collette S; Unsal-Kacmaz K; Broughton E; Zardavas D; Koon HB; Galsky MD
    N Engl J Med; 2021 Jun; 384(22):2102-2114. PubMed ID: 34077643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
    Bellmunt J; Mullane SA; Werner L; Fay AP; Callea M; Leow JJ; Taplin ME; Choueiri TK; Hodi FS; Freeman GJ; Signoretti S
    Ann Oncol; 2015 Apr; 26(4):812-817. PubMed ID: 25600565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
    Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
    BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.